Markets:

Overview

News

Currencies

International

Treasuries

BioNTech SE - American Depositary Shares (NQ:BNTX)

96.48 -0.80 (-0.82%)

Streaming Delayed Price Updated: 3:23 PM EST, Dec 9, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about BioNTech SE - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9

...

70 71 Next >

BioNTech to Acquire Biotheus to Boost Oncology Strategy

November 13, 2024

From BioNTech SE

Via GlobeNewswire

BioNTech Earns Upgrade From Goldman Sachs As Investment Thesis Shifts Toward Cancer Potential ↗

November 09, 2024

Goldman Sachs upgrades BioNTech to Buy, highlighting the potential of its cancer drug BNT327 and forecasting strong future revenue amid shifting company focus.

Via Benzinga

What Analysts Are Saying About BioNTech Stock ↗

November 08, 2024

Via Benzinga

This Bank of America Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday ↗

November 08, 2024

Via Benzinga

Trump's Potential 'Health Czar' Robert F. Kennedy Jr. Rattles Vaccine Stocks: 'Shoot First Reaction' ↗

November 07, 2024

Donald Trump has said he will give Robert F. Kennedy Jr. a senior role in his incoming administration to advance his "Make America Healthy Again" agenda.

Via Benzinga

Topics Government

Breaking Down BioNTech: 16 Analysts Share Their Views ↗

November 06, 2024

Via Benzinga

Forecasting The Future: 15 Analyst Projections For BioNTech ↗

October 07, 2024

Via Benzinga

BioNTech Se (BNTX) Q3 2024 Earnings Call Transcript ↗

November 04, 2024

BNTX earnings call for the period ending September 30, 2024.

Via The Motley Fool

Topics Earnings

BioNTech Variant-adapted COVID-19 Vaccines Do Well In Q3 ↗

November 04, 2024

BioNTech's Q3 revenue surged to €1.244 billion, reflecting early COVID-19 vaccine approvals. Net profit rose to €198.1 million, and full-year guidance adjusted downward.

Via Benzinga

BioNTech Jumps On Surprise Profit, Wide Sales Beat; But Lowers Outlook ↗

November 04, 2024

The company now expects sales to come in at the lower end of its previous guidance.

Via Investor's Business Daily

BioNTech Announces Third Quarter 2024 Financial Results and Corporate Update

November 04, 2024

From BioNTech SE

Via GlobeNewswire

As Stock Market Awaits Election, Palantir, S&P 500 Nuke Leaders Report ↗

November 01, 2024

Amid the election, and a Fed rate vote, earnings season roars ahead.

Via Investor's Business Daily

Topics Economy Stocks

BioNTech to Host Innovation Series R&D Day on November 14, 2024

October 31, 2024

From BioNTech SE

Via GlobeNewswire

Up Over 600% in 2024, Can Summit Therapeutics Stock Keep Rising? ↗

October 24, 2024

This drugmaker's lead candidate could become a top-selling cancer therapy.

Via The Motley Fool

FDA Presses Clinical Hold Button For BioNTech's Partner Late-Stage Trial Of Investigational Lung Cancer Treatment ↗

October 21, 2024

BioNTech's Phase 3 NSCLC trial is paused after varying outcomes. Current participants continue treatment, and other trials remain unaffected.

Via Benzinga

BioNTech to Report Third Quarter 2024 Financial Results and Corporate Update on November 4, 2024

October 21, 2024

From BioNTech SE

Via GlobeNewswire

Moderna Hit With Another Lawsuit Related To Key COVID-19 Vaccine Technology ↗

October 17, 2024

Northwestern University has filed a lawsuit against Moderna, alleging the company used its patented lipid nanoparticle technology without permission in the development of its COVID-19 vaccines.

Via Benzinga

Topics Lawsuit

GSK Sues Moderna Alleging mRNA Vaccine Patent Infringement ↗

October 15, 2024

GlaxoSmithKline has filed a lawsuit against Moderna, claiming its mRNA vaccines infringe on GSK's patents. GSK seeks royalties for Moderna's alleged unlicensed use of its groundbreaking vaccine...

Via Benzinga

Topics Intellectual Property Lawsuit

Pfizer Jumps After Activist Investor Starboard Reportedly Takes $1 Billion Stake ↗

October 07, 2024

Shares peaked near 62 in late 2021, but are now worth less than half of that.

Via Investor's Business Daily

4 Reasons Pfizer Could Be a Value Play You Can't Miss

October 07, 2024

Pfizer Inc. (NYSE: PFE) hit its peak during the COVID-19 pandemic when its vaccines developed with BioNTech SE (NASDAQ: BNTX) sent shares surging up to $61.71

Via MarketBeat

Uber To Rally Over 33%? Here Are 10 Top Analyst Forecasts For Monday ↗

October 07, 2024

Via Benzinga

Consumer Tech News (Sept 30-Oct 4): Latest Windows 11 Update Causing Trouble, Apple Accused Of Compelling Employees To Sign Illegal Agreements & More ↗

October 06, 2024

Major tech companies lobby against CA bill regulating AI, Apple faces legal complaints, iPhone users retain devices longer. Google warns Apple app removal.

Via Benzinga

Topics Artificial Intelligence Law Enforcement

Google DeepMind, BioNtech Unveil AI Lab Assistants To Revolutionize Scientific Research ↗

October 02, 2024

This AI aims to facilitate interdisciplinary collaboration and uncover unexpected connections in scientific research.

Via Benzinga

Topics Artificial Intelligence

BioNTech Highlights AI Capabilities and R&D Use Cases at Inaugural AI Day

October 01, 2024

From BioNTech SE

Via GlobeNewswire

Exxon Mobil To $120? Here Are 10 Top Analyst Forecasts For Tuesday ↗

September 24, 2024

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

September 23, 2024

Via Benzinga

Novo Nordisk, Chewy And FedEx Are Among Top 10 Large Cap Losers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio? ↗

September 22, 2024

10 large-cap stocks worst performers in last week: SMMT -23.61%, KSPI -21.66%, BMRN -16.74%, RIVN -13.26%, FDX -11.08%, BNTX -9.01%, AJG -7.17%, CHWY -6.97%, NVO -6.93%, MUSA -6.90%

Via Benzinga

Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-adapted COVID-19 Vaccine in the European Union

September 20, 2024

From Pfizer Inc.

Via Business Wire

Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-adapted COVID-19 Vaccine in the European Union

September 20, 2024

From BioNTech SE

Via GlobeNewswire

How BioNTech, Up 25% Over Four Days, Is Riding Summit's Coattails To A Recovery ↗

September 17, 2024

BioNTech is developing a drug similar to Summit's and shares have skyrocketed over the past four trading days.

Via Investor's Business Daily

< Previous 1 2 3 4 5 6 7 8 9

...

70 71 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.